Lulizumab

Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft[1][2].

Product Specifications

CAS Number

[2235419-62-0]

Product Name Alternative

Humanized Anti-CD28 Recombinant Antibody

UNSPSC

12352203

Target

CD28

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lulizumab.html

Purity

95.0

Solubility

H2O

Smiles

[Lulizumab]

Molecular Weight

(12.01 kDa)

References & Citations

[1]Fernandes JC. Therapeutic application of antibody fragments in autoimmune diseases: current state and prospects. Drug Discov Today. 2018 Dec;23 (12) :1996-2002.|[2]Schroder PM, et al. Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. Kidney Int. 2021 Jan;99 (1) :161-172.